{"filings":[{"id":1056280,"accession_number":"0001140361-26-025207","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-06-15T20:00:41+00:00","items":["1.01","1.02","2.03","3.02","3.03","9.01"],"status":"ready","headline":"PDS Biotechnology closes $6M promissory note, warrant, and $50M ATM facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $6M promissory note with YA II PN, Ltd.; net proceeds $5.76M after 4% OID.","Note bears 10% interest, matures June 15, 2027 (12 months from June 15, 2026).","Issued warrant to purchase 2,158,274 shares at $1.1824 per share, exercisable after 6 months for 5 years.","Entered $50M at-the-market offering agreement with Yorkville Securities and B. Riley Securities; 3% commission.","Redeemed and terminated all outstanding Senior Secured Convertible Debentures (issued April 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1039005,"accession_number":"0001140361-26-025121","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-06-15T12:00:30+00:00","items":["8.01"],"status":"ready","headline":"PDS Biotech schedules 2026 annual meeting for August 10","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["2026 annual meeting of stockholders set for August 10, 2026.","Stockholder proposals due by June 25, 2026 under Rule 14a-8.","Proposals must be sent to Corporate Secretary at Princeton, NJ address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":804556,"accession_number":"0001140361-26-023698","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-06-02T19:35:05+00:00","items":["8.01"],"status":"ready","headline":"PDS Biotech regains Nasdaq minimum bid price compliance as of June 2, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified PDS Biotech on June 2, 2026 that it regained compliance with the $1.00 minimum bid price rule.","The company had fallen below $1.00 for 30 consecutive business days, triggering a deficiency letter on Feb 25, 2026.","Nasdaq has closed the matter; no further compliance actions required for this issue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49963,"accession_number":"0001140361-26-020934","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-05-13T11:05:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.","R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.","VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.","PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.","New US and Japan patents granted for PDS0101, extending market protection into 2040s."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93032,"accession_number":"0001140361-26-018464","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","1.02","2.03","3.02"],"status":"ready","headline":"PDS Biotechnology issues $6M promissory note and warrant to YA II PN, redeems existing debentures","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $6M promissory note at 10% interest, 12-month maturity, issued at $5.76M (96% of face).","Issued warrant for 2,158,274 shares at $1.1824, exercisable after 6 months for 5 years.","Redeeming existing Senior Secured Convertible Debentures at 103% of principal plus accrued interest on June 12, 2026.","Terminated prior sales agreement with B. Riley and H.C. Wainwright; entered new ATM with Yorkville Securities.","Note includes conversion rights upon default at discounted VWAP; warrant has cashless exercise option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93031,"accession_number":"0001140361-26-016684","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotechnology updates corporate presentation deck; no material operational or financial changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing indicates only an updated investor presentation (Exhibit 99.1) was published.","No new clinical data, partnership, or financial metrics provided in the filing.","Slide deck cover: 'Precision Designed Science for Cancer Patients' with April 2026 date.","Investors should rely on prior disclosures for current business outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93030,"accession_number":"0001140361-26-014693","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports 78% ORR for PDS01ADC in MSS mCRC liver metastases trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stage 1 of Phase 2 NCI-led trial: 77.8% ORR (7/9) with PDS01ADC plus HAIP vs 35% in parallel study without PDS01ADC.","PDS01ADC plus HAIP showed ~85% 2-year survival rate; comparator arm had ~40% for MSS/pMMR metastatic colorectal cancer.","Extrahepatic progression-free survival median not reached at 13.1 months minimum follow-up; comparator median 8.1 months.","Data published in JCO Oncology Advances March 10, 2026; trial enrolls patients who failed at least one prior treatment.","MSS/pMMR colorectal liver metastases represent ~95% of mCRC where checkpoint inhibitors have failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104326,"accession_number":"0001140361-26-011862","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech reports FY2025 net loss of $34.5M, updates PDS0101 Phase 3 with interim PFS endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.5M ($0.74/share) vs $37.6M ($1.03/share) in 2024; cash $26.7M at year-end.","Amended VERSATILE-003 Phase 3 protocol to add PFS as interim endpoint; aims for accelerated approval and reduced trial cost.","PDS01ADC in mCRPC showed median PFS 9.6 months, PSA decline 40% in early NCI-led Phase 2 data.","New US and Japan patents for PDS0101 extend market protection into 2040s."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104325,"accession_number":"0001140361-26-007478","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"PDS Biotechnology receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1.00 for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.","Company has 180 calendar days, until August 24, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by deadline, company may seek a second 180-day period if it meets other listing standards.","Potential remedies include a reverse stock split; delisting could occur if compliance is not achieved.","Common stock continues trading on Nasdaq under symbol PDSB with no immediate impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104324,"accession_number":"0001140361-26-006410","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotechnology updates corporate presentation deck; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed corporate presentation dated February 2026 under Item 8.01.","Presentation title: 'Precision Designed Science for Cancer Patients'.","No specific clinical, financial, or strategic updates provided in the filing.","Confidence is low as only the title slide of the deck is visible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104323,"accession_number":"0001140361-26-006229","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech amends Phase 3 VERSATILE-003 trial to add PFS endpoint for potential accelerated approval of PDS0101","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Adopted protocol amendment for Phase 3 VERSATILE-003 trial adding progression-free survival as interim primary endpoint.","PFS endpoint supports potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer.","Median overall survival remains primary endpoint for full approval, per prior FDA Type C meeting.","FDA 30-day review period ended without objection; company proceeding with amended protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104322,"accession_number":"0001140361-26-002608","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech: NCI-led Phase 2 study of PDS01ADC shows median PFS 9.6 months in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 9.6 months (range 4.3-32.2) for PDS01ADC plus docetaxel in 3rd-line mCRPC patients.","Median PSA decline of 40%; 6 of 16 patients achieved >50% PSA decline.","Data presented at AACR special conference on prostate cancer (Boston, Jan 20-22, 2026).","Study by NCI/NIH evaluating PDS01ADC synergy with docetaxel in advanced prostate cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104321,"accession_number":"0001140361-26-001958","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech receives U.S. patent allowance for PDS0101 with 20-year market protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. Patent Office issued Notice of Allowance for PDS0101 (Application 16/210,750) covering cationic lipid compositions.","New patent plus biologics exclusivity expected to provide ~20 years of market protection for PDS0101.","PDS0101 is in Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancers.","Company submitted FDA protocol amendment proposing PFS as primary endpoint for potential accelerated approval.","IP estate includes granted patents in U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104320,"accession_number":"0001140361-26-000786","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech Submits FDA Protocol Amendment for Phase 3 VERSATILE-003, PFS Endpoint for Accelerated Approval","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On January 9, 2026, PDS Biotech submitted a protocol amendment to the FDA for its Phase 3 VERSATILE-003 trial.","The amendment changes progression free survival (PFS) to a primary endpoint for earlier evaluation, potentially enabling accelerated approval of PDS0101.","Median overall survival remains the primary endpoint for full approval as originally recommended by FDA.","The amendment follows a constructive Type C meeting with the FDA in December 2025.","The amendment is supported by positive final results from VERSATILE-002 trial showing promising mOS and durable PFS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120621,"accession_number":"0001140361-25-044940","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech receives broad Japanese patent for lead candidate PDS0101","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Japan Patent Office issued Patent No. 7783866 for PDS0101 covering broad composition of matter and methods of use.","Patent expands PDS Biotech's IP portfolio in Japan; previously granted patents in US, China, Australia, Hong Kong.","Company anticipates patent and market protections for PDS0101 into the 2040s, including US biologics exclusivity.","PDS0101 is in Phase 3 trial for HPV16-positive recurrent/metastatic head and neck cancer.","CEO Frank Bedu-Addo stated the patent strengthens global IP and supports growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120620,"accession_number":"0001140361-25-043889","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech schedules FDA Type C meeting to discuss accelerated approval for PDS0101 in HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted Type C meeting request; meeting scheduled for December 2025.","Agenda: proposed amendment to Phase 3 VERSATILE-003 for accelerated approval of PDS0101.","Amendment would change PFS to surrogate primary endpoint; mOS remains for full approval.","Based on positive VERSATILE-002 data showing mOS and durable PFS in CPS≥1 patients.","Company expects FDA meeting minutes in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120619,"accession_number":"0001140361-25-041805","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech Q3 net loss $9.0M; Phase 2 mOS 39.3 months; seeks accelerated approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $9.0M ($0.19/share) vs $10.7M ($0.29) YoY; R&D expenses down to $4.6M.","Cash $26.2M at Sep 30, 2025 vs $41.7M Dec 2024; raised ~$5.3M on Nov 12 stock/warrant sale.","VERSATILE-002 Phase 2 complete: mOS 39.3 months, PFS 6.3 months in CPS≥1 HNSCC patients.","Plans to amend VERSATILE-003 Phase 3 to seek accelerated approval with PFS as surrogate endpoint.","Colorectal cancer cohort of PDS01ADC met Stage 2 expansion criteria (≥6 of 9 objective responses)."],"consensus_eps_estimate":-0.2176,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120618,"accession_number":"0001140361-25-041563","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"PDS Biotech launches up to $11.1M registered direct offering; Sep 30 cash $26.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5.8M shares (or pre-funded warrants) at $0.91 with warrants exercisable at $1.00 per share.","Initial gross proceeds ~$5.3M; up to additional $5.8M if warrants fully exercised.","Proceeds for VERSATILE-003 Phase 3 trial and FDA discussions for accelerated PDS0101 pathway.","Existing warrants amended: exercise price reduced from $1.50 to $1.00, exercisable six months after close.","60-day lock-up agreements for directors and officers; Craig-Hallum as placement agent at 6.0% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120617,"accession_number":"0001140361-25-041286","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports positive translational data for PDS0101 and PDS01ADC at SITC 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Translational study of PDS0101 combo in 50 patients shows multiple serum biomarkers predict clinical benefit accurately.","PDS01ADC monotherapy increases NK cells with tumor-killing phenotypes and decreases poor-response NK cells in advanced solid tumors.","PDS01ADC increases self-replicating stem-like memory T cells (CD8 and CD4) associated with disease stabilization in 28 patients.","Data selected among top 150 abstracts at SITC; presented under NCI CRADA collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120616,"accession_number":"0001140361-25-039656","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech requests FDA meeting to discuss expedited approval for PDS0101 in HPV16+ HNSCC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Final VERSATILE-002 data: median PFS 6.3 months, median OS 39.3 months in recurrent/metastatic HPV16+ HNSCC.","Proposes amending Phase 3 VERSATILE-003 trial to add PFS as earlier primary endpoint for potential accelerated approval.","VERSATILE-003 temporarily paused during FDA review; currently enrolled patients continue treatment.","FDA meeting requested to expedite regulatory pathway based on strong survival results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137219,"accession_number":"0001140361-25-035339","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports 29.5-month median OS in low PD-L1 head and neck cancer cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival (mOS) of 29.5 months in CPS 1-19 cohort from VERSATILE-002 Phase 2 trial.","Published mOS for Keytruda monotherapy was 10.8 months; for Keytruda plus chemo 12.3 months.","Approximately 60% of trial patients (n=32) had low PD-L1 expression, a historically difficult-to-treat subset.","Data suggests PDS0101 + Keytruda may eliminate need for chemotherapy in this population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137218,"accession_number":"0001140361-25-032503","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotechnology files routine corporate presentation update; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated its investor presentation deck on August 25, 2025 (Exhibit 99.1).","The filing contains no new financial results, clinical data, or guidance changes.","Presentation covers previously announced precision oncology pipeline, no new milestones.","No material events such as earnings, M&A, regulatory actions, or leadership changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137217,"accession_number":"0001140361-25-032433","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports mOS 39.3 months in VERSATILE-002 Phase 2 vs 17.9 months standard of care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival of 39.3 months (lower bound 23.9) in CPS≥1 patients with HPV16+ HNSCC; standard pembrolizumab ± chemo mOS is 17.9 months.","53 patients enrolled; no discontinuations due to treatment-related adverse events.","Phase 3 VERSATILE-003 trial is underway based on these results.","Durable multifunctional HPV16-specific CD8+ T cells induced by PDS0101 observed across demographics.","Full data set to be published later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137216,"accession_number":"0001140361-25-030701","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech reports Q2 net loss $9.4M, clinical updates on PDS0101 and PDS01ADC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.4M ($0.21/dil share) vs $8.3M ($0.23) in Q2 2024.","R&D $4.2M, G&A $3.4M; total operating expenses $7.6M vs $8.7M.","Cash $31.9M (6/30/25) vs $41.7M (12/31/24); net interest expense $1.8M vs $0.5M.","Colorectal cancer cohort of Phase 2 trial with PDS01ADC met expansion criteria (≥6 of 9 objective responses).","Phase 3 VERSATILE-003 trial for PDS0101 in HPV16+ HNSCC progressing; 3 ASCO 2025 abstracts presented."],"consensus_eps_estimate":-0.238,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137215,"accession_number":"0001140361-25-025409","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech colorectal cancer cohort in NCI-led Phase 2 trial of PDS01ADC meets criteria for Stage 2 expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stage 1 of NCI-led Phase 2 trial for PDS01ADC + FUDR/HAIP in metastatic colorectal cancer met RECIST v1.1 criteria for expansion.","6 of 9 patients achieved objective response in Stage 1, triggering Simon two-stage design expansion to up to 22 patients.","Enrollment in Stage 2 for colorectal cancer cohort underway; completion targeted by Q4 2025.","Two other cohorts (cholangiocarcinoma, adrenocortical cancer) continue enrolling in Stage 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154513,"accession_number":"0001140361-25-023644","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotechnology updates corporate presentation; no financial or clinical data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K on June 25, 2025, with updated corporate presentation as Exhibit 99.1.","Presentation titled 'Addressing the Growing Incidence of HPV16-Related Cancers' and 'Precision Designed Science For Immunotherapy'.","No new financial results, clinical trial data, or guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154512,"accession_number":"0001140361-25-022212","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"PDSB stockholders approve amendment increasing equity plan shares by 3.14M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stephen Glover and Gregory Freitag elected as Class A directors at annual meeting.","Amendment to 2014 Equity Incentive Plan approved, adding 3,144,049 shares for total 9,709,584.","Ratification of KPMG US LLP as auditor for FY2025 passed with 25.6M votes for.","Advisory vote on named executive officer compensation approved, with 8.98M votes for.","About 65.97% of outstanding shares (30.1M) voted, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154511,"accession_number":"0001140361-25-021032","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports durable 30.0-month median OS from VERSATILE-002 in HPV16+ HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival (mOS) steady at 30.0 months with ~4.5 months additional follow-up; lower 95% CI increased to 23.9 months.","Median PFS: 6.3 months; ORR: 35.8%; disease control rate: 77.4%; median DoR: 21.8 months.","VERSATILE-003 is the only ongoing Phase 3 trial specifically addressing 1L r/m HPV16-positive HNSCC.","Data presented at ASCO 2025; no new safety signals; 22 of 53 patients still being followed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154510,"accession_number":"0001140361-25-020206","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports positive extended follow-up data for Versamune HPV Phase 2 in head and neck cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VERSATILE-002: mOS of 39.3 months (CPS≥20) vs ~15 months for pembrolizumab; median follow-up 18.4 months.","mOS of 30.0 months (CPS≥1) and 29.5 months (CPS 1-19), exceeding historical pembrolizumab results.","Phase 3 VERSATILE-003 (n=351) enrolling; primary endpoint mOS with two interim analyses planned.","Phase 2 window trial: 70% stable disease with Versamune HPV alone; 100% SD/PR with combo; met ctDNA endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154509,"accession_number":"0001140361-25-018800","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech Q1 net loss $8.5M; Phase 3 VERSATILE-003 trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($0.21 per share) in Q1 2025 vs $10.6M ($0.30) in Q1 2024; R&D expenses fell to $5.8M.","Cash and equivalents $40M as of March 31, 2025; includes $11M from Feb 2025 registered direct offering with warrants for up to $11M more.","VERSATILE-003 Phase 3 trial initiated for Versamune HPV + pembrolizumab in HPV16-positive HNSCC; targets ~350 patients with 2:1 randomization.","FDA cleared IND for Versamune MUC1 + PDS01ADC in metastatic colorectal cancer; NCI to lead Phase 1/2 under CRADA.","Three Versamune HPV abstracts selected for presentation at 2025 ASCO Annual Meeting (May 30-June 3)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154508,"accession_number":"0001140361-25-017870","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports preclinical flu vaccine data with Infectimune at IMMUNOLOGY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Infectimune-based flu vaccine elicited multifunctional, influenza-specific CD4 T cells with cytotoxic characteristics in preclinical studies.","Preclinical ferret studies showed neutralization of H3N2 influenza strains from 2014 to 2021 using COBRA antigens.","Studies were funded by NIAID's CIVR-HRP and presented by Dr. Sant (U of Rochester) and Dr. Allen (Cleveland Clinic).","Company reaffirms focus on VERSATILE-003 Phase 3 trial for Versamune HPV in HPV16-positive HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154507,"accession_number":"0001140361-25-017011","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"PDS Biotech closes $22.2M convertible debenture + warrant financing; repays Horizon loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $22.2M face-value Senior Secured Convertible Debentures (net $20M) to buyers including JGB Partners LP.","Proceeds used to retire ~$19M Horizon Technology Finance loan; remainder for general corporate purposes.","Debentures mature April 20, 2028; interest at prime rate +5% (min 6%), convertible at $2.52/share.","Warrants to purchase 1M shares at $2.52/share (100% premium to 5-day VWAP), exercisable for 10 years.","Company must maintain cash balance ≥ lesser of $15M or outstanding principal plus $3M; restrictive covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154506,"accession_number":"0001140361-25-015424","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Sir Richard Sykes to retire at PDS Biotechnology's 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sir Richard Sykes notified the Board on April 22, 2025, of his retirement.","He will not stand for re-election when his term expires at the 2025 Annual Meeting.","No replacement has been announced; Board composition will change accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173061,"accession_number":"0001140361-25-010575","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech reports FY2024 net loss $37.6M; initiates Phase 3 Versamune HPV trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2024 was $37.6M ($1.03 per share), compared to $42.9M ($1.39 per share) in 2023; operating expenses decreased to $36.3M from $43.0M.","Initiated Phase 3 VERSATILE-003 trial for Versamune HPV in HPV16-positive first-line recurrent/metastatic HNSCC; ~350 patients, primary endpoint overall survival.","FDA cleared IND for combination of Versamune MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma; Phase 1/2 with NCI.","Cash balance as of Dec 31, 2024 was $41.7M; subsequent $22M registered direct offering in Feb 2025 with $11M upfront proceeds.","FDA granted Fast Track designation for Versamune HPV + pembrolizumab combination in recurrent/metastatic HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173060,"accession_number":"0001140361-25-008557","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech announces FDA clearance of IND for Versamune MUC1 + PDS01ADC to treat metastatic colorectal cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for Versamune MUC1 (formerly PDS0103) + PDS01ADC to treat MUC1-positive unresectable metastatic colorectal carcinoma in failed prior treatment.","Phase 1/2 trial will be led by the National Cancer Institute under a CRADA with PDS Biotech.","MUC1 is over-expressed in colon, pancreatic, ovarian, breast, and NSCLC; study targets MSS mCRC, which accounts for 95% of mCRC patients.","U.S. Patent #12,201,685 covers methods of using Versamune platform and immunocytokines including PDS01ADC.","Company's primary focus remains on VERSATILE-003 Phase 3 trial in HPV16-positive head and neck squamous cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173059,"accession_number":"0001140361-25-007516","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech initiates VERSATILE-003 Phase 3 trial for Versamune HPV in head and neck cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial VERSATILE-003 now open to patient enrollment for HPV16-positive head and neck cancer.","Trial to enroll ~350 patients at 2:1 ratio; primary endpoint is overall survival.","First-ever Phase 3 trial in HPV16-positive head and neck cancer.","Versamune HPV already has FDA Fast Track designation based on Phase 2 data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173058,"accession_number":"0001140361-25-006423","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PDS Biotech raises $11M in registered direct offering; warrants could add $11M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$11M upfront from sale of 7.33M shares and warrants; warrants exercisable at $1.50/share for 5 years.","Up to an additional $11M if all warrants are exercised for cash.","Directors participated at $1.66/unit; institutional investors at $1.50/unit.","Net proceeds ~$10.05M intended for R&D and general corporate purposes.","Closing expected Feb 28, 2025; insiders subject to 60-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173057,"accession_number":"0001140361-25-005994","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech reports mOS of 42.4 months in ICI-naïve patients in JAMA Oncology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival 42.4 months in ICI-naïve patients vs. historical 7-12 months; for HPV16+ ICI-naïve, mOS not yet reached.","Confirmed ORR of 75% by irRECIST in HPV16+ ICI-naïve patients vs. historical 12-24%.","Median OS 17 months in ICI-resistant HPV16+ patients vs. historical 3-4 months; ORR 62.5% at high PDS01ADC dose.","Grade 3/4 treatment-related adverse events in 52% of patients; no treatment-related deaths.","Phase 3 VERSATILE-003 trial of Versamune HPV + pembrolizumab in head and neck cancer expected to start next month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173056,"accession_number":"0001140361-25-005571","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech announces Versamune® HPV ctDNA results: 100% clearance vs 50% CRT alone; Phase 3 HNSCC trial planned Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Versamune® HPV + CRT achieved 100% HPV16 ctDNA clearance at 3-4 months vs 50% with CRT alone in cervical cancer.","Undetectable ctDNA at 3-4 months linked to 93% 2-year recurrence-free survival vs 30% with detectable ctDNA.","Phase 3 VERSATILE-003 trial in HPV16-positive HNSCC to be initiated in Q1 2025.","Plans to discuss accelerated regulatory pathway (e.g., Breakthrough Therapy) with FDA based on ctDNA-survival correlation.","Median follow-up 23 months; 100% 36-month OS in patients receiving 5 doses of Versamune® HPV + CRT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173055,"accession_number":"0001140361-25-003082","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech Reaffirms Guidance to Initiate VERSATILE-003 Phase 3 Trial in Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared amended trial design for VERSATILE-003 Phase 3 trial of Versamune HPV plus pembrolizumab in HPV16-positive R/M HNSCC.","First site initiation expected in Q1 2025; FDA comment window has passed and company on track.","Fast Track designation from FDA for the combination in recurrent/metastatic HNSCC.","Companion diagnostic to confirm HPV16-positive status will be used in patient screening.","Guidance reaffirmed on February 5, 2025 via press release and corporate presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190088,"accession_number":"0001140361-24-046731","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PDS Biotech reports Q3 net loss $10.7M; modifies Phase 3 trial design to cut costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M ($0.29/share) vs $10.8M ($0.35/share) in Q3 2023; operating expenses declined slightly.","Cash and equivalents $49.8M as of Sept 30, 2024; cash runway supports VERSATILE-003 launch.","Phase 3 VERSATILE-003 trial design modified: ~350 patients, 2:1 randomization, overall survival primary endpoint.","Amended IND submitted Nov 2024; FDA clearance expected by mid-Dec; site activation targeted Q1 2025.","R&D expenses $6.8M (+$0.4M YoY) on higher manufacturing; G&A $3.4M (-$0.7M YoY) on lower personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190087,"accession_number":"0001140361-24-042537","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PDS Biotech: 84.4% 36-month OS in cervical cancer trial of Versamune HPV + chemoradiation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["36-month OS rate 84.4% (all patients) vs ~64% historical; 100% in 8 patients receiving all 5 doses.","36-month PFS rate 74.9% overall, 100% in fully dosed subgroup; historical ~61%.","Complete metabolic response (CMR) in 88% (15/17) of patients at 4 months per PET.","Versamune HPV well-tolerated; most common related AE injection site reaction (71%).","Median follow-up 19 months; data presented at ASTRO 2024, awarded Basic/Translational Science Award."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206586,"accession_number":"0001140361-24-041166","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotechnology posts updated corporate presentation; no new specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Form 8-K to update the corporate presentation deck on September 16, 2024.","Exhibit 99.1 contains the September 2024 corporate presentation, but detailed content was not provided in the filing.","No financial, clinical, or operational milestones were explicitly described in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206585,"accession_number":"0001140361-24-041102","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PDS Biotech reports updated VERSATILE-002 trial data: mOS 30 months, ORR 36%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival 30 months vs published 12-18 months for pembrolizumab alone.","Objective response rate 36% (19/53); disease control rate 77% (41/53).","21% of patients (11/53) had 90-100% tumor shrinkage; 9% (5/53) complete response.","Phase 3 VERSATILE-003 trial comparing combo vs pembrolizumab monotherapy planned to start in 2024.","Treatment well tolerated; Grade ≥3 AEs in 9 patients (Grade 3 n=8, Grade 4 n=1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206584,"accession_number":"0001140361-24-037073","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"PDS Biotechnology enters $50M ATM equity offering program with B. Riley and H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New at-the-market sales agreement allows up to $50M in common stock through B. Riley Securities and H.C. Wainwright.","Replaces prior August 2022 ATM program; 3% commission on gross proceeds to agents.","Shares sold via Rule 415 at-the-market on Nasdaq Capital Market; no minimum sales obligation.","Prior ATM agreement with B. Riley and BTIG terminated effective August 13, 2024.","Proceeds from any future sales will be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206583,"accession_number":"0001140361-24-036940","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PDS Biotech Q2 net loss narrows to $8.3M; FDA aligned on Phase 3 trial for Versamune HPV in HNSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.3M ($0.23/share) vs $11.5M ($0.37/share) YoY; R&D expenses down 44% to $4.5M.","Cash and equivalents $57.7M as of June 30, 2024.","FDA alignment achieved on Phase 3 VERSATILE-003 trial design for Versamune HPV + pembrolizumab; start Q4 2024.","Updated VERSATILE-002 data shows median OS of 30 months; abstracts accepted at ESMO, ASTRO, ICIS 2024.","Total operating expenses reduced to $8.7M from $12.7M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206582,"accession_number":"0001140361-24-036288","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech to present updated Versamune HPV Phase 2 data at ASTRO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated IMMUNOCERV Phase 2 data for Versamune® HPV (PDS0101) with chemoradiation in locally advanced cervical cancer accepted for oral presentation at ASTRO 2024.","Presentation scheduled for Oct 1, 2024, 2:50-3:00 p.m. ET; lead author Dr. Adam Grippin from MD Anderson.","No specific efficacy results disclosed in this press release; investors await presentation for updated data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206581,"accession_number":"0001140361-24-036026","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech to announce Q2 2024 results on August 13, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will report Q2 2024 financial results and provide business update before market open on August 13, 2024.","Press release will be available on the Investor Relations section of PDS Biotech's website.","No financial figures, guidance changes, or material updates included in this pre-announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206580,"accession_number":"0001140361-24-035618","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech VERSATILE-002 abstract accepted for ESMO 2024 presentation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract on first-line Versamune HPV + KEYTRUDA in HPV16-positive recurrent/metastatic HNSCC accepted for ESMO.","Poster number 879P; session at ESMO Congress 2024 in Barcelona, Sept 13-17.","Presenting author: Dr. Jared Weiss, Section Chief at UNC and trial PI.","Poster title includes survival data; no clinical results disclosed in this release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206579,"accession_number":"0001140361-24-035211","cik":1472091,"company_name":"PDS Biotechnology Corp","ticker":"PDSB","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PDS Biotech aligns with FDA on Phase 3 VERSATILE-003 trial for HPV16-positive HNSCC; initiation in Q4 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received official FDA minutes supporting Phase 3 trial of Versamune HPV + pembrolizumab for first-line recurrent/metastatic HPV16-positive HNSCC.","FDA agreed to separate PDS01ADC dose optimization to avoid delay; VERSATILE-003 proceeds as a 2-arm double combination registrational trial.","Phase 3 VERSATILE-003 trial to begin enrollment in Q4 2024; primary endpoint is overall survival.","Versamune HPV + pembrolizumab combination holds FDA Fast Track designation for this indication.","Corporate presentation updated; management cites matured VERSATILE-002 survival data supporting revised statistical endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":66141546.85135135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-01T23:59:59+00:00|206579"}